- Chaired by Katharine Whartenby, Ph.D., members include experts
in molecular medicine, aging, pathology and oncology
Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its
proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a
clinical stage pharmaceutical company committed to extending
healthy lifespan by focusing on developing two therapeutic
platforms, has completed the formation of its Scientific Advisory
Board (SAB). The board will be chaired by Katharine Whartenby,
Ph.D., associate professor at the Johns Hopkins University School
of Medicine Department of Neurology, Department of Oncology and in
Cellular and Molecular Medicine.
“Each member of our Scientific Advisory Board was hand-selected
for their wealth of knowledge and passion in the areas of
autoimmune, aging and age-related diseases,” said Chris Chapman,
M.D., President and Chief Medical Officer at MyMD
Pharmaceuticals.
“I’m honored to work alongside true leaders in these fields,”
said Katharine Whartenby, Ph.D., Chair of the Scientific Advisory
Board. “We have an excellent opportunity to help shepherd MyMD
Pharmaceuticals’ pipeline of therapeutic platforms to address many
of the unmet needs in medical treatment today.”
“I am excited to be in a position to help shape the development
of MYMD-1 through my experience in studying age-related conditions
such as sarcopenia and physical frailty,” said member Jeremy
Walston, M.D.
Members of the MyMD Scientific Advisory Board include:
Chair, Katharine Whartenby, Ph.D., The Johns Hopkins
University School of Medicine
Katharine Whartenby, Ph.D., is an associate professor in the
Department of Neurology, Department of Oncology and in Cellular and
Molecular Medicine at The Johns Hopkins University School of
Medicine.
Jeremy Walston, M.D., The Johns Hopkins University School of
Medicine
Jeremy Walston, M.D., is the Raymond and Anna Lubin Professor of
Geriatric Medicine and Gerontology at the Johns Hopkins University
School of Medicine, Director at the Biology of Healthy Aging
Program and Co-Principal Investigator of the Older American
Independence Center.
Scott Freeman, M.D., Co-Founder and Clinical Advisor at
MindMed
Scott Freeman, M.D., is a physician- scientist with extensive
experience in laboratory and clinical therapeutics development. He
has been a leader in research and development in academic and
industry settings and most recently co-founded MindMed. His
experience in clinical trial design and implementation along with
his FDA regulatory strategy will provide an invaluable
contribution.
Ryan Vandrey, Ph.D., The Johns Hopkins University School of
Medicine
Ryan Vandrey, Ph.D., is a professor of Psychiatry and Behavioral
Sciences. Dr. Vandrey's research focuses primarily on the
behavioral pharmacology of cannabis (marijuana) and includes
controlled laboratory studies with adult research volunteers,
clinical trials, web-based survey research, and natural history
studies with patient populations using cannabis/cannabinoids for
therapeutic purposes.
Alison O’Mahony, Ph.D., Eurofins Discovery
Alison O’Mahony, Ph.D., is the Vice President of Translational
Biology in the Phenotypic Services Unit of Eurofins Discovery. She
has extensive expertise in translational biology in the areas of
autoimmunity, inflammation, fibrosis, immuno-oncology (I-O),
cardiovascular, skin, pulmonary diseases and oncology.
Anupama Kumar, M.B.B.S., The Johns Hopkins University School
of Medicine
Anupama Kumar, M.B.B.S., is a Research Associate, Department of
Psychiatry and Behavioral Sciences, Johns Hopkins School of
Medicine. Anupama is also the Co-Director of Johns Hopkins TREAT
Depression Clinic and is skilled in planning and running Phase II
and III clinical trials.
About MyMD Pharmaceuticals, Inc.
MyMD is a clinical stage pharmaceutical company committed to
extending healthy lifespan by focusing on developing two
therapeutic platforms. MYMD-1 is a drug platform based on a
clinical stage small molecule that regulates the immunometabolic
system to control TNF-α and other pro-inflammatory cytokines.
MYMD-1 is being developed to treat autoimmune diseases, including
those currently treated with non-selective TNF-α blocking drugs,
and aging and longevity. SUPERA-CBD is a drug platform based on a
novel (patent pending) synthetic derivative of cannabidiol (CBD)
that targets numerous key receptors including CB2 and opioid
receptors and inhibits monoamine oxidase. SUPERA-CBD is being
developed to address the rapidly growing CBD market, that includes
FDA approved drugs and CBD products not currently regulated as a
drug. For more information, visit www.mymd.com.
No Offer or Solicitation
This communication shall not constitute an offer to sell or the
solicitation of an offer to sell or the solicitation of an offer to
buy any securities, nor shall there be any sale of securities in
any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction. No public offer of
securities shall be made except by means of a prospectus meeting
the requirements of Section 10 of the Securities Act of 1933, as
amended.
Important Additional Information for Investors and
Stockholders
In connection with the proposed transaction between Akers and
MyMD, Akers has filed with the SEC a registration statement on Form
S-4 that includes a proxy statement and prospectus of Akers. The
registration statement was declared effective by the SEC on March
23, 2021, and the proxy statement of Akers and prospectus was
mailed to the stockholders of Akers on or about March 24, 2021.
Akers may also file other relevant documents with the SEC regarding
the proposed transaction. AKERS URGES INVESTORS AND STOCKHOLDERS TO
READ THE DEFINITIVE PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT
DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN
THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT
INFORMATION ABOUT AKERS, THE PROPOSED TRANSACTION AND RELATED
MATTERS. Investors and shareholders may obtain free copies of the
proxy statement, prospectus and other documents filed by Akers with
the SEC through the website maintained by the SEC at www.sec.gov.
In addition, investors and shareholders may obtain free copies of
the proxy statement, prospectus and other documents filed by Akers
with the SEC by contacting Investor Relations by mail at Akers
Biosciences, Inc., Attn: Investor Relations, 1185 Avenue of the
Americas, 3rd Floor, New York, New York USA 10036. Investors and
stockholders are urged to read the proxy statement, prospectus and
the other relevant materials before making any voting or investment
decision with respect to the proposed transaction.
Participants in the Solicitation
Akers and MyMD, and each of their respective directors and
executive officers and certain of their other members of management
and employees, may be deemed to be participants in the solicitation
of proxies in connection with the proposed transaction. Information
about Akers’ directors and executive officers is included in Akers’
Annual Report on Form 10-K for the year ended December 31, 2020,
filed with the SEC on March 1, 2021. Additional information
regarding these persons and their interests in the transaction is
included in the definitive proxy statement/prospectus referred to
above. These documents can be obtained free of charge from the
sources indicated above.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this communication regarding
matters that are not historical facts are forward-looking
statements within the meaning of Section 21E of the Securities and
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995, known as the PSLRA. These include
statements regarding management’s intentions, plans, beliefs,
expectations or forecasts for the future, and, therefore, you are
cautioned not to place undue reliance on them. No forward-looking
statement can be guaranteed, and actual results may differ
materially from those projected. Akers and MyMD undertake no
obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise,
except to the extent required by law. We use words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions of the PSLRA.
Such forward-looking statements are based on our expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including, but not limited to, risks
relating to the completion of the merger, including the need for
stockholder approval and the satisfaction of closing conditions;
the cash balances of the combined company following the closing of
the merger; the ability of Akers to remain listed on the Nasdaq
Capital Market in connection with the merger; and expected
merger-related cash outlays, including the timing and amount of
those outlays. Risks and uncertainties related to MyMD that may
cause actual results to differ materially from those expressed or
implied in any forward-looking statement include, but are not
limited to: the timing of, and MyMD’s ability to, obtain and
maintain regulatory approvals for clinical trials of MyMD’s
pharmaceutical candidates, the timing and results of MyMD’s planned
clinical trials for its pharmaceutical candidates, the amount of
funds MyMD requires for its pharmaceutical candidates; increased
levels of competition; changes in political, economic or regulatory
conditions generally and in the markets in which MyMD operates;
MyMD’s ability to retain and attract senior management and other
key employees; MyMD’s ability to quickly and effectively respond to
new technological developments; MyMD’s ability to protect its trade
secrets or other proprietary rights, operate without infringing
upon the proprietary rights of others and prevent others from
infringing on MyMD’s proprietary rights; and the impact of the
ongoing COVID-19 pandemic on MyMD’s results of operations, business
plan and the global economy.
New factors emerge from time to time and it is not possible for
us to predict all such factors, nor can we assess the impact of
each such factor on the business or the extent to which any factor,
or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements.
These risks, as well as other risks associated with the
combination, are more fully discussed in the definitive proxy
statement/prospectus referred to above. Additional risks and
uncertainties are identified and discussed in the “Risk Factors”
section of Akers’ Annual Report on Form 10-K, Quarterly Reports on
Form 10-Q and other documents filed from time to time with the SEC.
Forward-looking statements included in this release are based on
information available to Akers and MyMD as of the date of this
release. Neither Akers nor MyMD undertakes any obligation to update
such forward- looking statements to reflect events or circumstances
after the date of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210412005550/en/
Investor Contact: Brett Mass 646-536-7331 brett@haydenir.com
www.haydenir.com
Media Contact: Will Johnson 201-465-8019 MYMD@antennagroup.com
www.antennagroup.com
Akers Biosciences (NASDAQ:AKER)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Akers Biosciences (NASDAQ:AKER)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
